European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer

European Journal of Cancer

Volumn 44, Issue 13, 2008, Pages 1807-1819

  Lordick, Florian ^a   Ruers, Theo ^b   Aust, Daniela E ^c   Collette, Laurence ^d   Downey, Robert J ^e   Hajjam, Mostafa El ^f   Flamen, Patrick ^g   Haustermans, Karen ^h   Ilson, David ^e   Julié, Catherine ⁱ   Krause, Bernd Joachim ^j   Newiger, Hartwig ^k   Ott, Katja ^a   Roth, Arnaud ^l   Cutsem, Eric Van ^h   Weber, Wolfgang A ^m   Lutz, Manfred P ⁿ  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d EORTC DATA CENTER   (Belgium)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f HÔPITAL AMBROISE PARÉ   (France)

^g JULES BORDET INSTITUTE   (Belgium)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^j TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^k SIEMENS AG   (Germany)

^l GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^m UNIVERSITY OF FREIBURG   (Germany)

ⁿ Caritasklinik St Theresia   (Germany)

more..

Author keywords

Gastrointestinal cancer; Imaging; Positron emission tomography; Response

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; EPIRUBICIN; ERLOTINIB; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; MATUZUMAB; PANITUMUMAB;

ALGORITHM; ARTICLE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER REGRESSION; CANCER RESEARCH; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIGESTIVE SYSTEM CANCER; EARLY DIAGNOSIS; ESOPHAGUS CARCINOMA; HISTOPATHOLOGY; HUMAN; LIVER METASTASIS; METASTASIS; MULTIDETECTOR COMPUTED TOMOGRAPHY; ORGANIZATION; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; RECTUM CANCER; RELIABILITY; REPRODUCIBILITY; STANDARDIZATION; STOMACH ADENOCARCINOMA; TREATMENT RESPONSE;

CLINICAL TRIALS AS TOPIC; CONSENSUS; EARLY DIAGNOSIS; EUROPE; GASTROINTESTINAL NEOPLASMS; HUMANS; NEOADJUVANT THERAPY; NUCLEAR MEDICINE; POSITRON-EMISSION TOMOGRAPHY; TREATMENT OUTCOME;

EID: 49849083956     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.06.005     Document Type: Article

References (49)

1. Medical Research Council Oesophageal Cancer Working Party, Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial, Lancet 359(2002) 1727-1733.
2. Cunningham D., Allum W.H., Stenning S.P., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New Engl J Med 355 (2006) 11-20
3. Gebski V., Burmeister B., Smithers B.M., et al. Survival benefi ts from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 8 (2007) 226-234
4. Folprecht G., Grothey A., Alberts S., et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 16 (2005) 1311-1319
5. Nordlinger B., Sorbye H., Glimelius B., et al. EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und - tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a:a randomised controlled trial. Lancet 371 (2008) 1007-1016
6. Kapiteijn E., Marijnen C.A., Nagtegaal I.D., et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. New Engl J Med 345 (2001) 638-646
7. Sauer R., Becker H., Hohenberger W., et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. New Engl J Med 351 (2004) 1731-1740
8. Kelsen D.P., Winter K.A., Gunderson L.L., Mortimer J., Estes N.C., Haller D.G., Ajani J.A., Kocha W., Minsky B.D., Roth J.A., and Willett C.G. Radiation Therapy Oncology Group; USA Intergroup. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by Surgery compared with surgery alone for esophageal cancer. J Clin Oncol 25 (2007) 3719-3725
9. Swisher S.G., Hofstetter W., Wu T.T., et al. Proposed revision of the esophageal cancer staging system to accommodate pathologic response following preoperative chemoradiation (CRT). Ann Surg 241 (2005) 810-820
10. Adam R., Delvart V., Pascal G., et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240 (2004) 644-657
11. Rödel C., Martus P., Papadoupolos T., et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23 (2005) 8688-8696
12. Benoist S., Brouquet A., Penna C., Julié C., et al. Complete response of colorectal liver metastases after chemotherapy: Does it mean cure?. J Clin Oncol 24 (2006) 3939-3945
13. Brown W.A., Thomas J., Gotley D., et al. Use of oesophagogastroscopy to assess the response of oesophageal carcinoma to neoadjuvant therapy. Br J Surg 91 (2004) 199-204
14. Reed C.E., Harpole D.H., Posther K.E., et al. Results of the American College of Surgeons Oncology Group Z0050 trial: The utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg 126 (2003) 1943-1951
15. Meyers B.F., Downey R.J., Decker P.A., et al. The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: Results of the American College of Surgeons Oncology Group Z0060 trial. J Thorac Cardiovasc Surg 133 (2007) 738-745
16. Downey R.J., Akhurst T., Gonen M., et al. Fluorine-18 fluorodeoxyglucose positron emission tomographic maximal standardised uptake value predicts survival independent of clinical but not pathologic TNM staging of resected non-small cell lung cancer. J Thorac Cardiovasc Surg. 133 (2007) 1419-1427
17. Lordick F., Ott K., Krause B., et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. The Lancet Oncology 8 (2007) 797-805
18. Weber W.A., Ziegler S.I., Thödtmann R., et al. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med. 40 (1999) 1771-1777
19. Stahl A., Ott K., Schwaiger M., et al. Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET. Eur J Nucl Med Mol Imaging 31 (2004) 1471-1478
20. Souvatzoglou M., Ziegler S.I., Martinez M.J., et al. Standardised uptake values from PET/CT images: comparison with conventional attenuation-corrected PET. Eur J Nucl Med Mol Imaging 34 (2007) 405-412
21. Ott K., Weber W.A., Lordick F., et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 24 (2006) 4692-4698
22. Ott K., Fink U., Becker K., et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 21 (2003) 4604-4610
23. Ott K., Herrmann K., Lordick F., et al. Early metabolic response evaluation by Fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res 14 (2008) 2012-2018
24. 18F]fluorothymidine (FLT) and FDG - a comparative analysis. J Nucl Med 48 (2007) 1945-1950
25. Baldus S.E., Mönig S.P., Schröder W., et al. Regression of oesophageal carcinomas after neoadjuvant radiochemotherapy: criteria of histopathological evaluation. Pathology 25 (2004) 421-427
26. Rubbia-Brandt L., Giostra E., Brezault C., et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 18 (2007) 299-304
27. Mandard A.M., Dalibard F., Mandard J.C., et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma clinicopathologic correlations. Cancer 73 (1994) 2680-2686
28. Becker K., Mueller J.D., Schuhmacher C., et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98 (2003) 1521-1530
29. Dworak O., Keilholz L., and Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 12 (1997) 19-23
30. Boige V., Pignon J.P., Saint-Aubert B., et al. Final results of a randomized trial comparing preoperative 5-fluorouracil/cisplatin to surgery alone in adenocarcinoma of the stomach and lower esophagus. J Clin Oncol 25 Suppl. 18S (2007) 4510 abstract
31. Stahl M., Walz M.K., Stuschke M., et al. Preoperative chemotherapy or radiochemotherapy in esophagogastric adenocarcinoma trial. J Clin Oncol 25 Suppl. 18S (2007) 4511 abstract
32. Stahl M., Stuschke M., Lehmann N., et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23 (2005) 2310-2317
33. Bedenne L., Michel P., Bouché O., et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 25 (2007) 1160-1168
34. Sakuramoto S., Sasako M., Yamaguchi T., et al. Adjuvant chemotherapy for gastric cancer, with S-1, and fluoropyrimidine. New Engl J Med 357 (2007) 1810-1820
35. Malthaner R., Colin S., and Fenlon D. Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst Rev 3 (2006) CD001556
36. Urschel J.D., and Vasan H. A meta analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 185 (2003) 538-543
37. Fiorica F., Di Bona D., Schepis F., et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and metaanalysis. Gut 53 (2004) 925-930
38. Van Cutsem E, Dicato M, Arber N, et al. The neo-adjuvant, surgical and adjuvant treatment of gastric adenocarcinoma. Current expert opinion derived from the Seventh World Congress on Gastrointestinal Cancer, Barcelona, 2005. Ann Oncol 2006;17 Suppl 6: vi13-18.
39. Van Cutsem E., Van de Velde C., Roth A., et al. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group. Eur J Cancer 44 (2008) 182-194
40. Macdonald J., Smalley S., Benedetti J., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. New Engl J Med 345 (2001) 725-730
41. Lubezky N., Metser U., Geva R., et al. The role and limitations of 18-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings. J Gastrointest Surg 11 (2007) 472-478
42. Koh D.M., Scurr E., Collins D., et al. Predicting response of colorectal hepatic metastasis: Value of pretreatment apparent diffusion coefficients. Am J Roentgenol 188 (2007) 1001-1008
43. Rullier A., Laurent C., Vendrely V., et al. Impact of colloid response on survival after preoperative radiotherapy in locally advanced rectal carcinoma. Am J Surg Pathol 29 (2005) 602-606
44. Weber W.A., and Figlin R. Monitoring cancer treatment with PET/CT: does it make a difference?. J Nucl Med 48 (2007) 36S-44S
45. Weber W.A., Ott K., Becker K., et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19 (2001) 3058-3065
46. Wieder H.A., Beer A.J., Lordick F., et al. Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. J Nucl Med 46 (2005) 2029-2034
47. Wieder H.A., Ott K., Lordick F., et al. Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction. Eur J Nucl Med Mol Imaging 34 (2007) 1925-1932
48. Wieder H.A., Geinitz H., Rosenberg R., et al. PET imaging with 18F3'-deoxy-3'-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging 34 (2007) 878-883
49. Collette L., Bosset J.F., den Dulk M., et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 25 (2007) 4379-4386